<DOC>
	<DOCNO>NCT01219816</DOCNO>
	<brief_summary>Patients relapsed/refractory adult acute lymphoblastic leukemia ( ALL ) dismal prognosis . In case , allogeneic transplantation curative treatment patient obtain second complete remission ( CR . In France , patient young 60 year old , HyperCVAD regimen use MDAnderson Houston generally apply . In old patient ( &gt; =60 year ) young patient &lt; = 60 year eligible intense chemotherapy , combination vincristine + Dexamethasone generally choose order avoid much toxicity result bad term CR . More 90 % ALL B phenotype ( 2/3 case adult ) express surface antigen CD22 leukemic blast thus represent interesting target therapy . Epratuzumab humanize anti-CD22 antibody produce Immunomedics , Inc , Morris Plain ( New Jersey , USA ) . Epratuzumab already show efficacy lymphoma patient . Only one study , include 15 child , publish far report efficacy toxicity Epratuzumab set ALL monotherapy , one observe 8 stable disease , 3 progression 4 partial response . When combine chemotherapy Epratuzumab , 9CR observe acceptable toxicity . Tolerance acceptable . The French GRAALL group propose test age-adapted combination chemotherapy + Epratuzumab , refractory/relapses CD22+ B ALL patient order improve prognosis , term CR , survival number patient eligible allograft .</brief_summary>
	<brief_title>Multi-centric Study</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &gt; = 18 year BALL ( OMs ) &gt; = 20 % blast bone marrow CD22+ expression &gt; = 30 % blast population Refractory BALL define treatment failure 2 successive course induction therapy relapse &lt; 6 month first CR First relapse BALL Second relapse beyond Performance status 02 Creatinine clearance &gt; = 50 ml/min ( Cockroft formula ) Serum bilirubine &lt; = 30 Âµmom/l Written inform consent TALL Meningeal involvement CD22 expression tumor cell &lt; 30 % HIV positive Active Hepatitis B C Left ventricular ejection fraction &lt; 50 % patient &lt; 60 year Contraindication Epratuzumab Previous concurrent second malignancy except adequately treat basal cell carcinoma skin , curatively treat situ carcinoma cervix , curatively treat solid cancer , evidence disease least 5 year Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Participation time another study investigational drug use Absence write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>efficacy Chemo-immunotherapy</keyword>
</DOC>